See more : PT Victoria Insurance Tbk (VINS.JK) Income Statement Analysis – Financial Results
Complete financial analysis of Edgewise Therapeutics, Inc. (EWTX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Edgewise Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- A.P. Møller – Mærsk A/S (MAERSK-B.CO) Income Statement Analysis – Financial Results
- Zota Health Care Limited (ZOTA.NS) Income Statement Analysis – Financial Results
- Hyundai Autoever Corporation (307950.KS) Income Statement Analysis – Financial Results
- Farmsco (036580.KS) Income Statement Analysis – Financial Results
- Mission Advancement Corp. (MACC) Income Statement Analysis – Financial Results
Edgewise Therapeutics, Inc. (EWTX)
About Edgewise Therapeutics, Inc.
Edgewise Therapeutics, Inc., a biopharmaceutical company, develops small molecule therapies for musculoskeletal diseases. The Company's lead product candidate, EDG-5506, is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy which has completed Phase 1 clinical trial. It develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics, Inc. was incorporated in 2017 and is headquartered in Boulder, Colorado.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 1.73M | 538.00K | 272.00K | 185.00K | 123.00K |
| Gross Profit | -1.73M | -538.00K | -272.00K | -185.00K | -123.00K |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 90.91M | 16.61M | 32.19M | 14.98M | 8.62M |
| General & Administrative | 23.45M | 5.47M | 11.03M | 2.21M | 1.30M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 23.45M | 5.47M | 11.03M | 2.21M | 1.30M |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 114.36M | 22.08M | 43.22M | 17.19M | 9.92M |
| Cost & Expenses | 114.36M | 22.08M | 43.22M | 17.19M | 9.92M |
| Interest Income | 14.19M | 2.66M | 402.00K | 69.00K | 219.00K |
| Interest Expense | 0.00 | 4.02M | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 1.73M | 538.00K | 272.00K | 185.00K | 123.00K |
| EBITDA | -112.81M | -67.10M | -42.94M | -17.01M | -9.80M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -114.36M | -22.08M | -43.22M | -17.19M | -9.92M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 14.19M | 4.02M | 402.00K | 69.00K | 219.00K |
| Income Before Tax | -100.16M | -19.42M | -42.81M | -17.12M | -9.71M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -4.02M | -674.00K | -69.00K | -219.00K |
| Net Income | -100.16M | -15.40M | -42.14M | -17.05M | -9.49M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -1.57 | -0.29 | -0.85 | -0.35 | -0.19 |
| EPS Diluted | -1.57 | -0.29 | -0.85 | -0.35 | -0.19 |
| Weighted Avg Shares Out | 63.72M | 53.59M | 49.50M | 49.22M | 49.22M |
| Weighted Avg Shares Out (Dil) | 63.72M | 53.59M | 49.50M | 49.22M | 49.22M |
Purple Innovation and Edgewise Therapeutics See Activist Investor Action
These disclosures are from 13Ds filed with the Securities and Exchange Commission. 13Ds are filed within 10 days of an entity's attaining more than 5% in any class of a company's securities.
Edgewise (EWTX) Up 9.37% on Positive Data From BMD Study
Edgewise (EWTX) stock gains on upbeat interim results from the ARCH study of its lead candidate EDG-5506 in adults with Becker Muscular Dystrophy (BMD).
Edgewise Therapeutics Announces Positive 4-Month Interim Results from the ARCH Open Label Study of EDG-5506 in Adults with Becker Muscular Dystrophy (BMD)
BOULDER, Colo.--(BUSINESS WIRE)--Edgewise Therapeutics, Inc., (NASDAQ: EWTX), a clinical-stage biopharmaceutical company focused on developing orally bioavailable, small molecule therapies for the treatment of rare muscle disorders, announced today positive 4-month interim results from the ongoing ARCH study, an open label,...
6 Blue-Chip Stocks to Sell Now
This article is about 6 blue-chip stocks to sell now. The stocks are overvalued or could fall due to the recession or from a downgrade in analysts' forecasts of their earnings.
RBC Capital Says This Dystrophy Stock 'Is Worth A Look'
RBC Capital says Edgewise Therapeutics Inc's (NASDAQ: EWTX) interim results from the ARCH study of EDG-5506 in Becker Muscular Dystrophy (BMD) improve reward/risk into October functional readout at 15 mg, which can help further de-risk the asset into the phase 2 BMD.
Edgewise Therapeutics Announces Positive 2-Month Interim Results from the ARCH Open Label Study of EDG-5506 in Adults with Becker Muscular Dystrophy (BMD)
BOULDER, Colo.--(BUSINESS WIRE)--Edgewise Therapeutics, Inc., (NASDAQ: EWTX), a clinical-stage biopharmaceutical company focused on developing orally bioavailable, small molecule therapies for the treatment of rare muscle disorders, announced today positive 2-month interim results from the ongoing ARCH study, an open label,...
Edgewise Therapeutics to Present at Upcoming Investor Conferences
BOULDER, Colo.--(BUSINESS WIRE)--Edgewise Therapeutics, Inc., (NASDAQ: EWTX), a clinical-stage biopharmaceutical company focused on developing orally bioavailable, small molecule therapies for the treatment of rare muscle disorders, announced today that members of its senior management team will participate in the following...
Edgewise Therapeutics Stock (EWTX): Why The Price Surged
The stock price of Edgewise Therapeutics Inc (NASDAQ: EWTX) increased by 22.47% in the most recent trading session. This is why it happened.
Edgewise Therapeutics Shares Jump After Positive Data On Becker Muscular Dystrophy Study
Edgewise Therapeutics Inc (NASDAQ: EWTX) posted positive topline results from Phase 1b trial of EDG-5506, designed to protect injury-susceptible fast skeletal muscle fibers in dystrophinopathies such as Duchenne muscular dystrophy (DMD) and Becker Muscular Dystrophy (BMD) The seven adults with BMD enrolled in...
Edgewise Therapeutics to Report Phase 1b Topline Results of EDG-5506 in Individuals with Becker Muscular Dystrophy (BMD) on January 5, 2022, and Initiates ARCH Follow-On Open Label BMD Study
BOULDER, Colo.--(BUSINESS WIRE)--Edgewise Therapeutics, Inc., (NASDAQ: EWTX), a clinical-stage biopharmaceutical company focused on developing orally bioavailable, small molecule therapies for the treatment of rare muscle disorders, today announced plans to report topline results from the Phase 1b clinical trial of...
Source: https://incomestatements.info
Category: Stock Reports